S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Aug

Today In Oncology

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced, Refractory Malignancies

Mosunetuzumab With Response-Adapted Therapy in Previously Untreated NHL

Study Supports Personalized Weight-Loss Intervention for Breast Cancer Survivors

Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment

County-Level Medical Debt Linked to Advanced-Stage Cancers, Worse Survival Among Newly Diagnosed U.S. Adults